Tetzlaff, Michael T.

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 4,812

Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,539

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Chen, P.-L., Roh, W., Reuben, A., Cooper, Z. A., Spencer, C. N., Prieto, P. A., Miller, J. P., Bassett, R. L., Gopalakrishnan, V., Wani, K., et al. (2016) · Cancer Discovery

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 988

Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

Spencer, C. N., McQuade, J. L., Gopalakrishnan, V., McCulloch, J. A., Vetizou, M., Cogdill, A. P., Khan, M. A. W., Zhang, X., White, M. G., Peterson, C. B., et al. (2021) · Science

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 966

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance

Roh, W., Chen, P.-L., Reuben, A., Spencer, C. N., Prieto, P. A., Miller, J. P., Gopalakrishnan, V., Wang, F., Cooper, Z. A., Reddy, S. M., et al. (2017) · Science Translational Medicine

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 859

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., et al. (2018) · Nature Medicine

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 835

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

Wang, Y., Wiesnoski, D. H., Helmink, B. A., Gopalakrishnan, V., Choi, K., DuPont, H. L., Jiang, Z.-D., Abu-Sbeih, H., Sanchez, C. A., Chang, C.-C., et al. (2018) · Nature Medicine

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 740

Mutational landscape of aggressive cutaneous squamous cell carcinoma

Pickering, C. R., Zhou, J. H., Lee, J. J., Drummond, J. A., Peng, S. A., Saade, R. E., Tsai, K. Y., Curry, J. L., Tetzlaff, M. T., Lai, S. Y., et al. (2014) · Clinical Cancer Research

Nonmelanoma Skin Cancer StudiesCancer Genomics and Diagnostics

Cited by 612

RETRACTED ARTICLE: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

Kaur, A., Webster, M. R., Marchbank, K., Behera, R., Ndoye, A., Kugel, C. H., Dang, V. M., Appleton, J., O’Connell, M. P., Cheng, P., et al. (2016) · Nature

Melanoma and MAPK PathwaysWnt/β-catenin signaling in development and cancer

Cited by 398

Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer

Blando, J., Sharma, A., Higa, M. G., Zhao, H., Vence, L., Yadav, S. S., Kim, J., Sepulveda, A. M., Sharp, M., Maitra, A., et al. (2019) · Proceedings of the National Academy of Sciences

Cancer Immunotherapy and BiomarkersPancreatic and Hepatic Oncology Research

Cited by 334

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

Amaria, R. N., Prieto, P. A., Tetzlaff, M. T., Reuben, A., Andrews, M. C., Ross, M. I., Glitza, I. C., Cormier, J., Hwu, W.-J., Tawbi, H. A., et al. (2018) · The Lancet Oncology

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 299

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma

Reuben, A., Spencer, C. N., Prieto, P. A., Gopalakrishnan, V., Reddy, S. M., Miller, J. P., Mao, X., De Macedo, M. P., Chen, J., Song, X., et al. (2017) · npj Genomic Medicine

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 166

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance

Somasundaram, R., Zhang, G., Fukunaga-Kalabis, M., Perego, M., Krepler, C., Xu, X., Wagner, C., Hristova, D., Zhang, J., Tian, T., et al. (2017) · Nature Communications

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 151

IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy

Johnson, D., Patel, A. B., Uemura, M. I., Trinh, V. A., Jackson, N., Zobniw, C. M., Tetzlaff, M. T., Hwu, P., Curry, J. L., & Diab, A. (2019) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersChemotherapy-related skin toxicity

Cited by 111

Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer

Reddy, S. M., Reuben, A., Barua, S., Jiang, H., Zhang, S., Wang, L., Gopalakrishnan, V., Hudgens, C. W., Tetzlaff, M. T., Reuben, J. M., et al. (2019) · Cancer Immunology Research

Breast Cancer Treatment StudiesBreast Lesions and Carcinomas

Cited by 106

Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity

Glitza, I. C., Seo, Y. D., Spencer, C. N., Wortman, J. R., Burton, E. M., Alayli, F. A., Loo, C. P., Gautam, S., Damania, A., Densmore, J., et al. (2024) · Cancer Discovery

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 87

Loss of microRNA-205 expression is associated with melanoma progression

Liu, S., Tetzlaff, M. T., Liu, A., Liegl-Atzwanger, B., Guo, J., & Xu, X. (2012) · Laboratory Investigation

MicroRNA in disease regulationCancer-related molecular mechanisms research

Cited by 74

miR‐200c/Bmi1 axis and epithelial–mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment

Liu, S., Tetzlaff, M. T., Wang, T., Yang, R., Xie, L., Zhang, G., Krepler, C., Xiao, M., Beqiri, M., Xu, W., et al. (2015) · Pigment Cell & Melanoma Research

Melanoma and MAPK PathwaysMicroRNA in disease regulation

Cited by 54

Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma

Tetzlaff, M. T., Adhikari, C., Lo, S., Rawson, R. V., Amaria, R. N., Menzies, A. M., Wilmott, J. S., Ferguson, P. M., Ross, M. I., Spillane, A. J., et al. (2020) · Annals of Oncology

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 37

Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma

Mitra, A., Andrews, M. C., Roh, W., De Macedo, M. P., Hudgens, C. W., Carapeto, F., Singh, S., Reuben, A., Wang, F., Mao, X., et al. (2020) · Nature Communications

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 27